NASDAQ:SLNO - Free Report ) by 162.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,418,093 shares of the company's stock after buying an additional 5,215,000 shares during the period. Soleno Therapeutics makes up about 27.7% of Vivo Capital LLC's investment portfolio, making the stock its biggest position. Vivo Capital LLC owned approximately 27.60% of Soleno Therapeutics worth $338,828,000 at the end of the most recent quarter.
Get Soleno Therapeutics alerts:
Sign Up
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Carlyle Group Inc. increased its holdings in Soleno Therapeutics by 24.6% during the fourth quarter. Carlyle Group Inc. now owns 2,857,804 shares of the company's stock worth $115,039,000 after buying an additional 564,242 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in Soleno Therapeutics during the 3rd quarter worth approximately $39,160,000. RA Capital Management L.P. bought a new stake in shares of Soleno Therapeutics in the 3rd quarter valued at about $36,563,000. Silverarc Capital Management LLC bought a new stake in Soleno Therapeutics during the third quarter valued at $10,919,000. Finally, Emerald Advisers LLC bought a new position in Soleno Therapeutics during the third quarter worth $7,338,000. 97.42% of the stock is owned by institutional investors.
Soleno Therapeutics Price Performance SLNO traded up $1.38 during midday trading on Thursday, reaching $47.64. 415,130 shares of the company's stock traded hands, compared to its average volume of 360,849. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -16.04 and a beta of -1.51. Soleno Therapeutics, Inc. has a 52 week low of $3.69 and a 52 week high of $53.82. The firm has a fifty day moving average of $42.57 and a two-hundred day moving average of $39.06.
Soleno Therapeutics (NASDAQ:SLNO - Get Free Report ) last issued its quarterly earnings results on Wednesday, March 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.02). Sell-side analysts forecast that Soleno Therapeutics, Inc. will post -1.23 EPS for the current year.
Wall Street Analyst Weigh In Several equities analysts have commented on SLNO shares. Stifel Nicolaus started coverage on shares of Soleno Therapeutics in a research report on Tuesday, January 23rd. They set a "buy" rating and a $63.00 target price on the stock. Piper Sandler initiated coverage on Soleno Therapeutics in a research report on Monday, February 5th. They set an "overweight" rating and a $93.00 price target on the stock. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $55.60.
Get Our Latest Research Report on Soleno Therapeutics
Insider Buying and Selling at Soleno Therapeutics In other Soleno Therapeutics news, insider Kristen Yen sold 2,218 shares of the business's stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $41.34, for a total transaction of $91,692.12. Following the completion of the transaction, the insider now owns 23,422 shares in the company, valued at $968,265.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link . In other news, major shareholder Vivo Opportunity, Llc sold 750,000 shares of Soleno Therapeutics stock in a transaction on Monday, April 29th. The shares were sold at an average price of $47.80, for a total transaction of $35,850,000.00. Following the completion of the sale, the insider now directly owns 7,668,093 shares in the company, valued at $366,534,845.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link . Also, insider Kristen Yen sold 2,218 shares of the company's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $41.34, for a total value of $91,692.12. Following the completion of the transaction, the insider now directly owns 23,422 shares in the company, valued at $968,265.48. The disclosure for this sale can be found here . Insiders sold a total of 776,373 shares of company stock valued at $36,940,260 in the last three months. 28.80% of the stock is currently owned by corporate insiders.
Soleno Therapeutics Company Profile (
Free Report )
Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
See Also
Before you consider Soleno Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Soleno Therapeutics wasn't on the list.
While Soleno Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
